All In Biotech

Drug Trial Radar · NCT00454480

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Planned (sponsor's estimate)

Start

Aug 2006

Primary completion

Aug 2012

Sponsor

Lead sponsor
The University of New South WalesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 30, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with gemtuzumab ozogamicin or tipifarnib may kill more cancer cells. PURPOSE: This randomized phase II/III trial is studying different combination chemotherapy regimens to compare how well they work when given with or without gemtuzumab ozogamicin or tipifarnib in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.

Conditions

  • Leukemia
  • Myelodysplastic Syndromes

Interventions

  • alemtuzumabBiological

  • arsenic trioxideDrug

  • azacitidineDrug

  • busulfanDrug

  • clofarabineDrug

  • cytarabineDrug

  • daunorubicin hydrochlorideDrug

  • fludarabine phosphateDrug

  • gemtuzumab ozogamicinDrug

  • melphalanDrug

  • tipifarnibDrug

  • DNA methylation analysisGenetic

  • cytogenetic analysisGenetic

  • gene expression analysisGenetic

  • mutation analysisGenetic

  • diagnostic laboratory biomarker analysisOther

  • immunologic techniqueOther

  • allogeneic hematopoietic stem cell transplantationProcedure

  • nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival
  2. Achievement of complete remission and reasons for failure
  3. Duration of remission, relapse rates, and deaths
  4. Hematological and nonhematological toxicity
  5. Supportive care requirements (and other aspects of health economics)

Locations

96 sites in 1 country. Site status is shown where the registry gives one.

  • Hereford Hospitals

    Hereford, United Kingdom

  • Wexham Park Hospital

    Slough, Berkshire, United Kingdom

  • Kingston Hospital

    Surrey, United Kingdom

  • Basingstoke and North Hampshire NHS Foundation Trust

    Basingstoke, England, United Kingdom

  • Royal United Hospital

    Bath, England, United Kingdom

  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, United Kingdom

  • Birmingham Heartlands Hospital

    Birmingham, England, United Kingdom

  • Blackpool Victoria Hospital

    Blackpool, England, United Kingdom

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom

  • Bradford Royal Infirmary

    Bradford, England, United Kingdom

  • Sussex Cancer Centre at Royal Sussex County Hospital

    Brighton, England, United Kingdom

  • Queen's Hospital

    Burton-on-Trent, England, United Kingdom

  • West Suffolk Hospital

    Bury St Edmunds, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Kent and Canterbury Hospital

    Canterbury, England, United Kingdom

  • St. Helier Hospital

    Carshalton, England, United Kingdom

  • Gloucestershire Oncology Centre at Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Countess of Chester Hospital

    Chester, England, United Kingdom

  • Chesterfield Royal Hospital

    Chesterfield, England, United Kingdom

  • Saint Richards Hospital

    Chichester, England, United Kingdom

  • Walsgrave Hospital

    Coventry, England, United Kingdom

  • Mayday University Hospital

    Croydon, England, United Kingdom

  • Derbyshire Royal Infirmary

    Derby, England, United Kingdom

  • Doncaster Royal Infirmary

    Doncaster, England, United Kingdom

  • Dorset County Hospital

    Dorchester, England, United Kingdom

  • Russells Hall Hospital

    Dudley, England, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, England, United Kingdom

  • Medway Maritime Hospital

    Gillingham Kent, England, United Kingdom

  • Harrogate District Hospital

    Harrogate, England, United Kingdom

  • Northwick Park Hospital

    Harrow, England, United Kingdom

  • Hemel Hempstead General

    Hemel Hempstead, England, United Kingdom

  • Wycombe General Hospital

    High Wycombe, England, United Kingdom

  • Hull Royal Infirmary

    Hull, England, United Kingdom

  • Ipswich Hospital

    Ipswich, England, United Kingdom

  • West Middlesex University Hospital

    Isleworth, England, United Kingdom

  • Kettering General Hosptial

    Kettering, Northants, England, United Kingdom

  • Kidderminster Hospital

    Kidderminster Worcestershire, England, United Kingdom

  • Crosshouse Hospital

    Kilmarnock, England, United Kingdom

  • Leeds General Infirmary

    Leeds, England, United Kingdom

  • Leicester Royal Infirmary

    Leicester, England, United Kingdom

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.